TABLE 1.

Serological results of 14 patients with neuroPCM and control groups evaluated by inh-ELISA, ID, and ELISA

SubjectCSF antigen concn (μg/ml)aCSF titer (ELISA)bSerum antigen concn (μg/ml)aAntibody titer (ID)
gp43gp70Anti-gp43Anti-gp70gp43gp70CSFSerum
Case 119.56.75+ (1:1,600)+ (1:1,600)NAdNANRcNA
Case 224.06.75+ (1:400)+ (1:50)NANANRNA
Case 30.460.43+ (1:200)+ (1:50)NANANRNA
Case 43.751.83+ (1:50)+ (1:50)2.851.03NRNR
Case 521.06.75+ (1:6,400)+ (1:400)5.271.49NR1:8
Case 618.04.16+ (1:200)+ (1:50)5.272.49NR1:4
Case 722.53.39+ (1:50)+ (1:50)01.03NRNA
Case 813.52.67+ (1:50)+ (1:50)1.210NRNA
Case 916.58.25+ (1:50)+ (1:50)4.161.77NR+NDSe
Case 1019.57.5+ (1:200)+ (1:50)1.0311.25NR+NDS
Case 1130.016.5+ (1:200)+ (1:50)4.161.68NRNR
Case 1230.013.5+ (1:50)+ (1:50)7.122.49NRNR
Case 1325.55.64+ (1:50)+ (1:50)12.758.25NRNR
Case 1425.56.38+ (1:51,200)+ (1:50)6.7511.251:161:16
Mean19.36.84.64.0
Control group Ag00(−)f(−)
Control group Bh00NRNR
  • a Antigen detection by inh-ELISA.

  • b Antibody detection by conventional ELISA.

  • c NR, nonreactive.

  • d NA, not available.

  • e +NDS, positive with nondiluted sera.

  • f (−), negative.

  • g Ten CSF samples from noninfectious neurologic diseases were negative for antigens and antibodies (control patients).

  • h Thirty serum samples from healthy volunteers were negative for antigens and antibodies (control patients).